13 results on '"Vallaster M"'
Search Results
2. A Consideration of Fixed Dosing Versus Body Size-Based Dosing Strategies for Chimeric Antigen Receptor T-Cell Therapies.
- Author
-
He JZ, Wang H, Lim K, Ren S, Rollins F, Vallaster M, Wong R, Stebbings R, Standifer N, Keefe R, Phipps A, and Gibbs M
- Subjects
- Body Size, Humans, Immunotherapy, Adoptive, T-Lymphocytes, Receptors, Chimeric Antigen
- Published
- 2022
- Full Text
- View/download PDF
3. Corrigendum: Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal.
- Author
-
Zhao-Shea R, DeGroot SR, Liu L, Vallaster M, Pang X, Su Q, Gao G, Rando OJ, Martin GE, George O, Gardner PD, and Tapper AR
- Published
- 2015
- Full Text
- View/download PDF
4. Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal.
- Author
-
Zhao-Shea R, DeGroot SR, Liu L, Vallaster M, Pang X, Su Q, Gao G, Rando OJ, Martin GE, George O, Gardner PD, and Tapper AR
- Subjects
- Animals, Habenula anatomy & histology, Male, Mice, Mice, Inbred C57BL, Nerve Net, Receptors, Corticotropin-Releasing Hormone genetics, Receptors, Corticotropin-Releasing Hormone metabolism, Signal Transduction physiology, Substance Withdrawal Syndrome physiopathology, Anxiety etiology, Corticotropin-Releasing Hormone metabolism, Habenula physiology, Interpeduncular Nucleus physiology, Nicotine adverse effects, Ventral Tegmental Area physiology
- Abstract
Increased anxiety is a prominent withdrawal symptom in abstinent smokers, yet the neuroanatomical and molecular bases underlying it are unclear. Here we show that withdrawal-induced anxiety increases activity of neurons in the interpeduncular intermediate (IPI), a subregion of the interpeduncular nucleus (IPN). IPI activation during nicotine withdrawal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expression and signalling, which modulated glutamatergic input from the medial habenula (MHb). Pharmacological blockade of IPN CRF1 receptors or optogenetic silencing of MHb input reduced IPI activation and alleviated withdrawal-induced anxiety; whereas IPN CRF infusion in mice increased anxiety. We identified a mesointerpeduncular circuit, consisting of ventral tegmental area (VTA) dopaminergic neurons projecting to the IPN, as a potential source of CRF. Knockdown of CRF synthesis in the VTA prevented IPI activation and anxiety during nicotine withdrawal. These data indicate that increased CRF receptor signalling within a VTA-IPN-MHb circuit triggers anxiety during nicotine withdrawal.
- Published
- 2015
- Full Text
- View/download PDF
5. Enhanced stem cell migration mediated by VCAM-1/VLA-4 interaction improves cardiac function in virus-induced dilated cardiomyopathy.
- Author
-
Brunner S, Theiss HD, Leiss M, Grabmaier U, Grabmeier J, Huber B, Vallaster M, Clevert DA, Sauter M, Kandolf R, Rimmbach C, David R, Klingel K, and Franz WM
- Subjects
- Animals, Cardiomyopathy, Dilated metabolism, Cardiomyopathy, Dilated virology, Coxsackievirus Infections, Disease Models, Animal, Echocardiography, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Granulocyte Colony-Stimulating Factor metabolism, Granulocyte Colony-Stimulating Factor pharmacology, Humans, Immunohistochemistry, Mice, Real-Time Polymerase Chain Reaction, Stem Cells cytology, Bone Marrow Cells cytology, Cardiomyopathy, Dilated physiopathology, Cell Movement physiology, Integrin alpha4beta1 metabolism, Vascular Cell Adhesion Molecule-1 metabolism
- Abstract
Endogenous circulation of bone marrow-derived cells (BMCs) was observed in patients with dilated cardiomyopathy (DCM) who showed cardiac upregulation of Vascular Cell Adhesion Protein-1 (VCAM-1). However, the underlying pathophysiology is currently unknown. Thus, we aimed to analyze circulation, migration and G-CSF-based mobilization of BMCs in a murine model of virus-induced DCM. Mice with coxsackievirus B3 (CVB3) induced DCM and healthy controls were analyzed regarding their myocardial homing factors by PCR. To determine cardiac VCAM-1 expression ELISA and immunohistochemistry were applied. Flow cytometry was performed to analyze BMCs. Cardiac diameters and function were evaluated by echocardiography before and 4 weeks after G-CSF treatment. In murine CVB3-induced DCM an increase of BMCs in peripheral blood and a decrease of BMCs in bone marrow was observed. We found an enhanced migration of Very Late Antigen-4 (VLA-4⁺) BMCs to the diseased heart overexpressing VCAM-1 and higher numbers of CD45⁻CD34⁻Sca-1⁺ and CD45⁻CD34⁻c-kit⁺ cells. Mobilization of BMCs by G-CSF boosted migration along the VCAM-1/VLA-4 axis and reduced apoptosis of cardiomyocytes. Significant improvement of cardiac function was detected by echocardiography in G-CSF-treated mice. Blocking VCAM-1 by a neutralizing antibody reduced the G-CSF-dependent effects on stem cell migration and cardiac function. This is the first study showing that in virus-induced DCM VCAM-1/VLA-4 interaction is crucial for recruitment of circulating BMCs leading to beneficial anti-apoptotic effects resulting in improved cardiac function after G-CSF-induced mobilization.
- Published
- 2013
- Full Text
- View/download PDF
6. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction.
- Author
-
Theiss HD, Gross L, Vallaster M, David R, Brunner S, Brenner C, Nathan P, Assmann G, Mueller-Hoecker J, Vogeser M, Steinbeck G, and Franz WM
- Subjects
- Adamantane administration & dosage, Animals, Cell Survival drug effects, Cell Survival physiology, Drug Therapy, Combination, Heart physiology, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Sitagliptin Phosphate, Vildagliptin, Adamantane analogs & derivatives, Granulocyte Colony-Stimulating Factor administration & dosage, Heart drug effects, Hypoglycemic Agents administration & dosage, Myocardial Infarction drug therapy, Nitriles administration & dosage, Pyrazines administration & dosage, Pyrrolidines administration & dosage, Triazoles administration & dosage
- Abstract
Background: Medical stimulation of endogenous progenitor cell circulation may serve as a new therapeutic tool for treatment of acute myocardial infarction. We analyzed the effects of antidiabetic gliptins plus GCSF (granulocyte colony stimulating factor) on myocardial regeneration after myocardial infarction in a mouse model., Methods and Results: After surgical LAD-ligation (left anterior descending artery), Sitagliptin/Vildagliptin was applied yielding sufficient blood levels verified by mass spectrometry and significantly reducing activity of dipeptidyl peptidase (DPP) IV. GCSF or saline was administered intraperitoneally for 6 days. We assessed stem cell mobilization and homing (flow cytometry), infarct size (histology), neovascularization and cellular proliferation (immunohistology), heart function (Millar tip catheterization) and survival (Kaplan-Meier-curves). Gliptins±GCSF administration increased mobilization and cardiac homing of bone-marrow derived stem cells by stabilization of cardiac SDF1 (stromal cell-derived factor). For Sitagliptin, it could be shown that resident cardiac stem cells were stimulated, neovascularization was enhanced and cardiac remodeling was reduced. These effects finally improved myocardial function and increased survival for both gliptins. Although gliptins as a mono therapy lead to remarkable effects in a dose dependent manner and were superior to G-CSF mono-therapy, dual application of GCSF and gliptins revealed the best results. Since both gliptins yielded comparable effects concerning stem cell homing, cardiac function and survival, we suggest a class-effect of DPP-IV-inhibitors., Conclusions: Thus, gliptins+GCSF and in high concentrations even as mono therapy have beneficial effects on cardiac regeneration after myocardial infarction beyond its anti-diabetic potential., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
7. Epigenetic mechanisms in cardiac development and disease.
- Author
-
Vallaster M, Vallaster CD, and Wu SM
- Subjects
- Abnormalities, Multiple genetics, Animals, CHARGE Syndrome genetics, Cell Differentiation, Chromatin metabolism, Chromosomal Proteins, Non-Histone metabolism, DNA Helicases metabolism, DiGeorge Syndrome genetics, Embryonic Stem Cells physiology, Gene Expression Regulation, Developmental physiology, Heart Defects, Congenital genetics, Heart Septal Defects, Atrial genetics, Homeobox Protein Nkx-2.5, Homeodomain Proteins genetics, Humans, Lower Extremity Deformities, Congenital genetics, Nuclear Proteins metabolism, Nucleosomes metabolism, Transcription Factors genetics, Transcription Factors metabolism, Upper Extremity Deformities, Congenital genetics, Wolf-Hirschhorn Syndrome genetics, Epigenesis, Genetic, Heart embryology, Heart Defects, Congenital embryology
- Abstract
During mammalian development, cardiac specification and ultimately lineage commitment to a specific cardiac cell type is accomplished by the action of specific transcription factors (TFs) and their meticulous control on an epigenetic level. In this review, we detail how cardiac-specific TFs function in concert with nucleosome remodeling and histone-modifying enzymes to regulate a diverse network of genes required for processes such as cell growth and proliferation, or epithelial to mesenchymal transition (EMT), for instance. We provide examples of how several cardiac TFs, such as Nkx2.5, WHSC1, Tbx5, and Tbx1, which are associated with developmental and congenital heart defects, are required for the recruitment of histone modifiers, such as Jarid2, p300, and Ash2l, and components of ATP-dependent remodeling enzymes like Brg1, Baf60c, and Baf180. Binding of these TFs to their respective sites at cardiac genes coincides with a distinct pattern of histone marks, indicating that the precise regulation of cardiac gene networks is orchestrated by interactions between TFs and epigenetic modifiers. Furthermore, we speculate that an epigenetic signature, comprised of TF occupancy, histone modifications, and overall chromatin organization, is an underlying mechanism that governs cardiac morphogenesis and disease.
- Published
- 2012
- Full Text
- View/download PDF
8. Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction.
- Author
-
Brunner S, Huber BC, Weinberger T, Vallaster M, Wollenweber T, Gerbitz A, Hacker M, and Franz WM
- Subjects
- Animals, Bone Marrow Cells cytology, Cell Separation methods, Green Fluorescent Proteins genetics, Green Fluorescent Proteins metabolism, Humans, Mice, Mice, Inbred C57BL, Mice, Transgenic, Vascular Endothelial Growth Factor A blood, Bone Marrow Cells drug effects, Bone Marrow Cells physiology, Cell Movement physiology, Erythropoietin pharmacology, Myocardial Infarction pathology
- Abstract
Erythropoietin (EPO) was shown to have protective effects after myocardial infarction (MI) by neovascularization and antiapoptotic mechanisms. Beside direct receptor-dependent mechanisms, mobilization and homing of bone marrow-derived cells (BMCs) may play a pivotal role in this regard. In this study, we intended to track different subpopulations of BMCs and to assess serially myocardial perfusion changes in EPO-treated mice after MI. To allow tracking of BMCs, we used a chimeric mouse model. Therefore, mice (C57BL/6J) were sublethally irradiated, and bone marrow (BM) from green fluorescent protein transgenic mice was transplanted. Ten weeks later coronary artery ligation was performed to induce MI. EPO was injected for 3 days with a total dose of 5000 IU/kg. Subpopulations (CD31, c-kit, CXCR-4 and Sca-1) of EGFP(+) cells were studied in peripheral blood, bone marrow and hearts by flow cytometry. Myocardial perfusion was serially investigated in vivo by pinhole single-photon emission computed tomography (SPECT) at days 6 and 30 after MI. EPO-treated animals revealed an enhanced mobilization of BMCs into peripheral blood. The numbers of these cells in BM remained unchanged. Homing of all BMCs subpopulations to the ischaemic myocardium was significantly increased in EPO-treated mice. Among the investigated subpopulations, EPO predominantly affected migration of CXCR-4(+) (4.3-fold increase). Repetitively SPECT analyses revealed a reduction of perfusion defects after EPO treatment over time. Our study shows that EPO treatment after MI enhances the migration capacity of BMCs into ischaemic tissue, which may attribute to an improved perfusion and reduced size of infarction, respectively., (© 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
9. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
- Author
-
Theiss HD, Vallaster M, Rischpler C, Krieg L, Zaruba MM, Brunner S, Vanchev Y, Fischer R, Gröbner M, Huber B, Wollenweber T, Assmann G, Mueller-Hoecker J, Hacker M, and Franz WM
- Subjects
- Animals, Antigens, CD34 metabolism, Benzylamines, Chemokine CXCL12 antagonists & inhibitors, Cyclams, Dipeptidyl Peptidase 4 metabolism, Dose-Response Relationship, Drug, Granulocyte Colony-Stimulating Factor pharmacology, Heart Function Tests drug effects, Heterocyclic Compounds pharmacology, Leukocyte Common Antigens metabolism, Mice, Models, Biological, Myocardial Infarction pathology, Myocardial Infarction physiopathology, Neovascularization, Physiologic drug effects, Oligopeptides pharmacology, Perfusion, Proto-Oncogene Proteins c-kit metabolism, Receptors, CXCR4 antagonists & inhibitors, Survival Analysis, Chemokine CXCL12 metabolism, Hematopoietic Stem Cell Mobilization, Myocardial Infarction therapy, Receptors, CXCR4 metabolism, Stem Cell Transplantation
- Abstract
Background: G-CSF based stem cell mobilization and stabilization of cardiac SDF-1 by DPP-IV-inhibition (dual stem cell therapy) improve heart function and survival after myocardial infarction. However, it is barely understood whether this new approach acts specifically through the SDF-1/CXCR4 axis, stimulation of resident cardiac stem cells and improved myocardial perfusion. Therefore, we aimed to clarify the role of the SDF1/CXCR4 axis with respect to the benefits of a dual stem cell based therapy., Methodology/principal Findings: After surgically induced ligation of the LAD, SDF-1/CXCR4 interactions were specifically blocked by the CXCR4 receptor antagonist AMD3100 in G-CSF and Diprotin A treated C57BL/6 mice. G-CSF+DipA treated and non-treated animals served as controls. Because AMD3100 is known to mobilize bone marrow derived stem cells (BMCs) in high concentrations, the optimal dosage (1.25mg per kg body weight) sufficient to block CXCR4 without stimulating mobilization was established. AMD3100 treatment of G-CSF and Diprotin A stimulated mice significantly decreased myocardial homing of circulating stem cells (FACS analysis) and inverted the beneficial effects of (i) cardiac remodeling (histological analyses), (ii) heart function (Millar tip catheterization) and (iii) survival (Kaplan-Meier curves). G-CSF treatment in combination with DPP-IV inhibition enhanced neovascularization at the infarct border zone which was related to an improved myocardial blood flow as measured by SPECT. Moreover, dual stem cell treatment effectively stimulated the pool of resident cardiac stem cells (FACS) which was reversed by AMD3100 treatment., Conclusions/significance: Our data give final proof that homing through the SDF-1/CXCR-4 axis is essential for the success of dual stem cell therapy., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
10. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart.
- Author
-
Huber BC, Brunner S, Segeth A, Nathan P, Fischer R, Zaruba MM, Vallaster M, Theiss HD, David R, Gerbitz A, and Franz WM
- Subjects
- Adult Stem Cells drug effects, Adult Stem Cells metabolism, Adult Stem Cells pathology, Animals, Benzylamines, Cardiotonic Agents pharmacology, Cyclams, Hematopoietic Stem Cells drug effects, Hematopoietic Stem Cells metabolism, Hematopoietic Stem Cells pathology, Heterocyclic Compounds pharmacology, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Myocardial Ischemia metabolism, Myocardial Ischemia pathology, Myocardial Ischemia prevention & control, Protease Inhibitors pharmacology, Receptors, CXCR4 antagonists & inhibitors, Regenerative Medicine methods, Chemokine CXCL12 metabolism, Dipeptidyl Peptidase 4 metabolism, Hematopoietic Stem Cell Mobilization methods, Myocardial Ischemia therapy, Parathyroid Hormone pharmacology, Receptors, CXCR4 metabolism
- Abstract
Aims: Parathyroid hormone (PTH) has been shown to promote stem cell mobilization into peripheral blood. Moreover, PTH treatment after myocardial infarction (MI) improved survival and myocardial function associated with enhanced homing of bone marrow-derived stem cells (BMCs). To unravel the molecular mechanisms of PTH-mediated stem cell trafficking, we analysed wild-type (wt) and green fluorescent protein (GFP)-transgenic mice after MI with respect to the pivotal stromal cell-derived factor-1 (SDF-1)/chemokine receptor type 4 (CXCR4) axis., Methods and Results: WT and GFP-transgenic mice (C57BL/6J) were infarcted by coronary artery ligation and PTH (80 μg/kg/day) was injected for 6 days afterwards. Number of BMCs was analysed by flow cytometry. SDF-1 protein levels and activity of dipeptidyl peptidase-IV (DPP-IV) were investigated by ELISA and activity assay. Functional analyses were performed at day 30 after MI. PTH-treated animals revealed an enhanced homing of CXCR4(+) BMCs associated with an increased protein level of the corresponding homing factor SDF-1 in the ischaemic heart. In vitro and in vivo, PTH inhibited the activity of DPP-IV, which cleaves and inactivates SDF-1. Functionally, PTH significantly improved myocardial function after MI. Both stem cell homing as well as functional recovery were reversed by the CXCR4 antagonist AMD3100., Conclusion: In summary, PTH is a DPP-IV inhibitor leading to an increased cardiac SDF-1 level, which enhances recruitment of CXCR4(+) BMCs into the ischaemic heart associated with attenuated ischaemic cardiomyopathy. Since PTH is already clinically used our findings may have direct impact on the initiation of studies in patients with ischaemic disorders.
- Published
- 2011
- Full Text
- View/download PDF
11. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.
- Author
-
Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, David R, Fischer R, Krieg L, Hirsch E, Huber B, Nathan P, Israel L, Imhof A, Herbach N, Assmann G, Wanke R, Mueller-Hoecker J, Steinbeck G, and Franz WM
- Subjects
- Animals, Apoptosis drug effects, Apoptosis physiology, Dipeptidyl Peptidase 4 genetics, Dipeptidyl Peptidase 4 metabolism, Granulocyte Colony-Stimulating Factor pharmacology, Heart physiology, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells drug effects, Kaplan-Meier Estimate, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Myocardial Infarction enzymology, Myocardial Infarction physiopathology, Neovascularization, Physiologic drug effects, Neovascularization, Physiologic physiology, Chemokine CXCL12 metabolism, Dipeptidyl-Peptidase IV Inhibitors, Granulocyte Colony-Stimulating Factor therapeutic use, Heart drug effects, Hematopoietic Stem Cells physiology, Myocardial Infarction drug therapy, Receptors, CXCR4 metabolism
- Abstract
Ischemic cardiomyopathy is one of the main causes of death, which may be prevented by stem cell-based therapies. SDF-1alpha is the major chemokine attracting stem cells to the heart. Since SDF-1alpha is cleaved and inactivated by CD26/dipeptidylpeptidase IV (DPP-IV), we established a therapeutic concept--applicable to ischemic disorders in general--by combining genetic and pharmacologic inhibition of DPP-IV with G-CSF-mediated stem cell mobilization after myocardial infarction in mice. This approach leads to (1) decreased myocardial DPP-IV activity, (2) increased myocardial homing of circulating CXCR-4+ stem cells, (3) reduced cardiac remodeling, and (4) improved heart function and survival. Indeed, CD26 depletion promoted posttranslational stabilization of active SDF-1alpha in heart lysates and preserved the cardiac SDF-1-CXCR4 homing axis. Therefore, we propose pharmacological DPP-IV inhibition and G-CSF-based stem cell mobilization as a therapeutic concept for future stem cell trials after myocardial infarction.
- Published
- 2009
- Full Text
- View/download PDF
12. Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow.
- Author
-
Brunner S, Zaruba MM, Huber B, David R, Vallaster M, Assmann G, Mueller-Hoecker J, and Franz WM
- Subjects
- Animals, Bone Marrow Cells classification, Cell Cycle drug effects, Granulocyte Colony-Stimulating Factor blood, Granulocyte Colony-Stimulating Factor pharmacology, Immunophenotyping, Male, Mice, Mice, Inbred C57BL, Parathyroid Hormone pharmacology, Vascular Endothelial Growth Factor A blood, Bone Marrow drug effects, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells drug effects, Parathyroid Hormone physiology
- Abstract
Objective: Cytokine-mediated mobilization of hematopoietic stem cells has become an established method in the field of autologous and allogenic stem cell transplantation. Furthermore, it presents a new concept in tissue repair and regenerative medicine. In the present study, we explored the potency of parathyroid hormone (PTH) compared to granulocyte colony-stimulating factor (G-CSF) for mobilization of stem cells and its regenerative capacity on bone marrow., Materials and Methods: Healthy mice were either treated with PTH, G-CSF, or saline. Laboratory parameters were analyzed using a hematological cell analyzer. Hematopoietic stem cells characterized by lin(-)/Sca-1(+)/c-kit(+), as well as subpopulations (CD31(+), c-kit(+), Sca-1(+), CXCR4(+)) of CD45(+)/CD34(+) and CD45(+)/CD34(-) cells were measured by flow cytometry. Immunohistology as well as fluorescein-activated cell sorting analyses were utilized to determine the composition and cell-cycle status of bone marrow cells. Serum levels of distinct cytokines (G-CSF, vascular endothelial growth factor [VEGF]) were determined by enzyme-linked immunosorbent assay. Further, circulating cells were measured after PTH treatment in combination with G-CSF or a G-CSF antibody., Results: Stimulation with PTH showed a significant increase of all characterized subpopulations of bone marrow-derived progenitor cells (BMCs) in peripheral blood (1.5- to 9.8-fold) similar to G-CSF. In contrast to G-CSF, PTH treatment resulted in an enhanced cell proliferation with a constant level of lin(-)/Sca-1(+)/c-kit(+) cells and CD45(+)/CD34(+) subpopulations in bone marrow. Interestingly, PTH application was associated with increased serum levels of G-CSF (2.8-fold), whereas VEGF showed no significant changes. Blocking endogenous G-CSF with an antibody significantly reduced the number of circulating cells after PTH treatment. A combination of PTH and G-CSF showed slight additional effects compared to PTH or G-CSF alone., Conclusion: PTH induces mobilization of progenitor cells effectively, which can be related to an endogenous release of G-CSF. In contrast to G-CSF treatment, PTH does not result in a depletion of bone marrow, which may be mediated by an activation of PTH receptor on osteoblasts. The novel function of PTH on mobilization and regeneration of BMCs may pave the way for new therapeutic options in bone marrow and stem cell transplantation as well as in the field of ischemic disorders.
- Published
- 2008
- Full Text
- View/download PDF
13. G-CSF treatment after myocardial infarction: impact on bone marrow-derived vs cardiac progenitor cells.
- Author
-
Brunner S, Huber BC, Fischer R, Groebner M, Hacker M, David R, Zaruba MM, Vallaster M, Rischpler C, Wilke A, Gerbitz A, and Franz WM
- Subjects
- Animals, DNA Primers, Disease Models, Animal, Flow Cytometry, Genes, Reporter, Green Fluorescent Proteins analysis, Green Fluorescent Proteins genetics, Hematopoietic Stem Cell Mobilization, Mice, Mice, Inbred C57BL, Mice, Transgenic, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Bone Marrow Transplantation methods, Granulocyte Colony-Stimulating Factor therapeutic use, Myocardial Infarction drug therapy, Myocardial Infarction surgery
- Abstract
Objective: Besides its classical function in the field of autologous and allogenic stem cell transplantation, granulocyte colony-stimulating factor (G-CSF) was shown to have protective effects after myocardial infarction (MI) by mobilization of bone marrow-derived progenitor cells (BMCs) and in addition by activation of multiple signaling pathways. In the present study, we focused on the impact of G-CSF on migration of BMCs and the impact on resident cardiac cells after MI., Materials and Methods: Mice (C57BL/6J) were sublethally irradiated, and BM from green fluorescent protein (GFP)-transgenic mice was transplanted. Coronary artery ligation was performed 10 weeks later. G-CSF (100 microg/kg) was daily injected for 6 days. Subpopulations of enhanced GFP(+) cells in peripheral blood, bone marrow, and heart were characterized by flow cytometry. Growth factor expression in the heart was analyzed by quantitative real-time polymerase chain reaction. Perfusion was investigated in vivo by gated single photon emission computed tomography (SPECT)., Results: G-CSF-treated animals revealed a reduced migration of c-kit(+) and CXCR-4(+) BMCs associated with decreased expression levels of the corresponding growth factors, namely stem cell factor and stromal-derived factor-1 alpha in ischemic myocardium. In contrast, the number of resident cardiac Sca-1(+) cells was significantly increased. However, SPECT-perfusion showed no differences in infarct size between G-CSF-treated and control animals 6 days after MI., Conclusion: Our study shows that G-CSF treatment after MI reduces migration capacity of BMCs into ischemic tissue, but increases the number of resident cardiac cells. To optimize homing capacity a combination of G-CSF with other agents may optimize cytokine therapy after MI.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.